glp-1 gip tirzepatide Beyond glycemia: Comparing to analogues 1+GIP — tailored just to you. Bridging the gap between GLP1-receptor

doi: 10.1016/j.bmc.2017.06.052

McGill HC, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, et al

However, for low-risk or moderate-risk patients, cardiovascular risk should be reassessed based on newly discovered target organ damage to determine management strategies

It is approved by the FDA for chronic weight management in adults with obesity (BMI 30), or overweight (BMI 27) with at least one weight-related condition, such as type 2 diabetes, high blood pressure, or high cholesterol

Mumphrey MB, Hao Z, Townsend RL, Patterson LM, Berthoud H-R

Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society